Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PCI domain containing protein 2 (PCID2)
- Target
- PCID2
- Molecular classification
- Other (component of the TREX-2 complex; does not fit standard receptor, enzyme, transporter, or transcription factor classes)
01
Overview
PCI domain containing protein 2 (PCID2) is a component of the TREX-2 (Transcription and Export complex 2), involved in nuclear export of mRNA and regulation of cell division checkpoint proteins such as Mad2/MAD2L1. It interacts with and stabilizes BRCA2 protein, controls B-cell survival during differentiation, and restricts lymphoid lineage commitment by modulating chromatin remodeling and gene expression. PCID2 acts as a proto-oncogene in colorectal cancer, promoting cell proliferation, migration, and invasion, while suppressing apoptosis; it mediates these effects primarily by degrading the tumor suppressor PML (promyelocytic leukemia protein), thereby activating canonical Wnt/β-catenin oncogenic signaling and inhibiting noncanonical β-catenin-ARF-p53 tumor-suppressive pathways. High expression or gene amplification of PCID2 is a negative prognostic marker for colorectal cancer recurrence. PCID2 is not currently considered a standard drug target (such as a receptor or enzyme), and there are no reported drugs that specifically interact with or inhibit this protein.
- Other names
- PCID2PCI domain-containing protein 2
02
Biological functions
mRNA export from nucleusRegulation of cell division checkpoint proteins (e.g., regulates Mad2/MAD2L1)Stabilization of BRCA2 (breast cancer 2) proteinRegulation of B-cell survival via cell cycle checkpoint proteinsRestriction of lymphoid lineage commitment (by regulating histone variant deposition and key fate regulators)
03
Disease associations
Cancer (promotes cell growth, cell cycle progression, migration/invasion, and suppresses apoptosis in colorectal cancer)Biomarker in colorectal cancer recurrence predictionAssociated with breast cancer and lung acinar adenocarcinoma
04
Biomarkers
PCID2 overexpression/levels as an independent predictor of colorectal cancer recurrence
Beyond the preview
Go deeper on PCI domain containing protein 2 (PCID2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCI domain containing protein 2 (PCID2).